Yaz is an oral contraceptive (combination birth control pill) that received U.S. Food and Drug Administration (FDA) approval in 2006 for use by women to prevent pregnancy. Approximately one to two out of 100 women may get pregnant during their first year taking Yaz, making it no more effective than older and usually less expensive pills. But for some women, Yaz doesn’t cause bloating or weight gain, two side effects that can be common with most birth control pills, making it a desirable contraceptive choice.
Yaz is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception. PMDD is a condition characterized by more severe symptoms than those associated with premenstrual syndrome (PMS). While Yaz is approved for the treatment of PMDD symptoms, it has not been evaluated for the treatment of PMS, nor has the effectiveness of Yaz for PMDD been evaluated for use for more than three menstrual cycles.
In 2007, the FDA expanded Yaz uses to include treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have experienced at least one period (menstruation). But in 2008, the FDA stated that Yaz’ presumed success in treating acne was “misleadingly overstate(d),” according to ABC News. And state authorities accused its manufacturer, Bayer, of “deceptive advertising.”
The new television ads, designed to clear up any misconceptions to consumers and reeducate patients on the actual benefits of taking Yaz, stated, “Yaz is for the treatment of premenstrual dysphoric disorder, or PMDD, and moderate acne, not for the treatment of PMS or mild acne.” The curative ads cost Bayer a total of $20 million, an amount agreed upon by the drug-making corporation and the DOJ.
In 2011, Bayer and Yaz faced controversy yet again, when multiple independent studies pointed to an increased risk of blood clots in patients taking the fourth-generation oral contraceptive compared to other leading birth control pills. In 2012, after the FDA completed its review of the observational studies, the federal agency concluded that drospirenone-containing birth control pills, such as Yaz, may in fact be associated with a higher risk (as high as a three-fold increase in risk) for blood clots than other progestin-containing pills.
How Does Yaz Work?
Yaz’ two active ingredients, drospirenone and ethinyl estradiol, prevent ovulation (the release of an egg from the ovaries) and cause changes in a woman’s cervical and uterine lining, making it harder for sperm to get to the uterus and meet with an egg, and more difficult for a fertilized egg to attach to the uterine wall. Ovulation is key for pregnancy, and without it, pregnancy cannot occur.
Yaz is different from most birth control pills because it contains a new generation of synthetic progesterone called drospirenone, which is closely related to spironolactone, a diuretic. Drospirenone is one of several different progestins that are used in birth control pills. Drospirenone also has anti-androgenic properties, which means it works against testosterone and other hormones.
Yaz is available in blister packs. It is the only combination oral contraceptive with 24 active pills that include hormones and four inactive pills. This gives the patient an increased dose of hormones during the month. Most birth control pills include seven inactive pills. Each of the 24 active pills is light pink and contains 3 mg drospirenone and 0.02 mg ethinyl estradiol as betadex clathrate. The four inactive tablets are white.
What Does Yaz Treat?
Yaz is approved to prevent pregnancy and treat PMDD. It has not been evaluated for the treatment of PMS, despite Bayer’s claims.
Yaz is indicated for use by women to prevent pregnancy. The FDA has also approved the birth control pill for the treatment of symptoms related to premenstrual dysphoric disorder (PMDD), in such women who choose to use an oral contraceptive as their method of contraception. Although the FDA advises that in making the diagnosis of PMDD, care should be taken to rule out other cyclical mood disorders before prescribing treatment with Yaz.
Yaz has not been evaluated for the treatment of premenstrual syndrome (PMS), despite previous marketing claims by its manufacturer Bayer. However, Yaz’ uses were extended in 2007 to include the treatment of moderate acne (or moderate acne vulgaris) in women at least 14 years of age who have had at least one period. According to the FDA, Yaz should be used for this purpose only if the patient also desires an oral contraceptive for birth control.
Premenstrual Dysphoric Disorder (PMDD) Versus Premenstrual Syndrome (PMS)
Every month, when a female begins ovulating, she experiences what is known as menstruation (a period), or the regular discharge of blood and shedding of mucosal tissue from the inner lining of the uterus through the vagina. Besides bleeding, a woman on her period may experience abdominal and pelvic pain and cramping, lower back pain, bloating, sore breasts, food cravings, acne, mood swings and irritability, headaches, or fatigue.
Premenstrual syndrome, or PMS, is a group of symptoms that start about one to two weeks before a woman’s period and can include emotional as well as physical symptoms. No one knows the exact cause of PMS, but hormonal changes can trigger the symptoms associated with it. Most women experience at least some symptoms of PMS, with the symptoms typically going away after their period starts.
But for some women, the symptoms can become so severe that they interfere with their lives. These women have a condition called premenstrual dysphoric disorder (PMDD). Johns Hopkins Medicine said that PMDD “may be an abnormal reaction to normal hormonal changes.” The hormone changes can cause a serotonin deficiency. Serotonin is a naturally occurring substance in the brain and intestines that can affect mood and cause physical symptoms.
These symptoms requiring attention include the following:
- Anxiety or tension
- Unstable, rapidly changing emotions
- Persistent anger and irritability
- Crying spells
- Trouble sleeping
- Fluid retention, including swelling of the ankles, hands and feet
- Nausea and/or vomiting
- Skin inflammation and/or itching
- Vision changes
- Dizziness and fainting
- Heart palpitations
- Appetite changes
- Hot flashes
- Hormonal changes that make the skin oilier (related to puberty, menstrual periods, pregnancy, birth control pills or stress)
- Greasy or oily cosmetic and hair products
- Certain drugs (such as steroids, testosterone, estrogen and phenytoin)
- Heavy sweating or humidity
Moderate Acne Vulgaris
Acne is a common skin disease that causes pimples, or zits, which are the result of clogged hair follicles (pores) under the skin. Most pimples form on the face, neck, back, chest and shoulders, and can appear as whiteheads, blackheads, or red, inflamed patches of skin. While acne is not a very serious condition, it can cause scars and unsightly blemishes that can be permanent, and acne that is deep in the skin can cause hard, painful cysts.
Acne can affect anyone, although it is most common in teenagers and young adults, but it tends to run in families. There are many mistruths about what causes acne, such as dirty skin and stress. Blackheads and pimples are not caused by dirt, and while stress can worsen acne, it is not the underlying cause of it.
Some also believe that chocolate and greasy foods may prompt pimples to appear. But research shows that chocolate, nuts and greasy foods rarely have an effect on acne in most people. Although diets high in refined sugars or dairy products may be related to acne in some people, according to the National Institutes of Health (NIH).
Some other common acne triggers may include:
Dosing and Administration: How to Take Yaz
The medication’s label instructs Yaz users to take one tablet daily by mouth at the same time every day. Tablets must be taken in the order directed on the blister pack.
The drug’s failure rate may increase when users miss pills or take the pills incorrectly. Single missed pills should be taken as soon as remembered, according to the label. Severe vomiting or diarrhea may affect absorption, and additional contraceptive measures should be taken in cases of gastrointestinal disturbances. If vomiting occurs within three to four hours after taking Yaz, this should be considered a missed dose, according to the instructions.
Instructions on how to start taking Yaz vary depending on when you plan to start the pack and whether you are switching from a different form of birth control. Women taking Yaz for the first time should take their first light pink pill on the first day of their period (Day1) or on the first Sunday after the onset of their period. Yaz should not be considered effective as a contraceptive until after you a have taken it for seven consecutive days.
If you start Yaz on the first day of your period, take one light pink Yaz daily for 24 consecutive days, followed by one inactive white tablet daily on days 25 through 28. You can take Yaz with or without food but it’s preferable to take it after an evening meal or at bedtime with some liquid.
If you start Yaz on the first Sunday after the start of your period, take one light pink Yaz daily for 24 consecutive days, followed by one inactive white tablet daily on days 25 through 28.
Switching from a Different Pill
If switching from another birth control pill, you should take Yaz on the same day that a new pack of the previous oral contraceptive would have been started.
Switching from a Different Method
If switching from a transdermal patch, vaginal ring or injection, you should start Yaz when the next application or next dose would have been due. If switching from an intrauterine contraceptive or an implant, you should start Yaz on the day of removal.
Postpartum women who do not breastfeed should start Yaz no earlier than four weeks after delivering a baby because of an increased risk of thromboembolism. Check for possible pregnancy before staring Yaz and use an additional method of contraception until you have taken Yaz for seven consecutive days. Do not take Yaz if you are pregnant.
Start the next pack — and all subsequent packs — the day after you finish the pack of you’re on and follow the same schedule. Take the light pink tablets the day after you take the last white tablet, regardless of whether or not a period has occurred or is still in progress. If you don’t start a new pack on the day after taking the last white tablet, you should use another method of contraception until you have taken a light pink Yaz tablet daily for seven consecutive days.
Who Should Not Take Yaz
Patients with preexisting kidney, liver or adrenal disease should not take Yaz because this could cause serious heart and health problems. Serum potassium levels should be checked in women starting Yaz because of the possibility of high potassium levels, called hyperkalemia. Because drospirenone is chemically similar to spironolactone, Yaz should not be used in patients with preexisting kidney problems.
Women who take long-term non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, should not take Yaz. Neither should women who had adrenal insufficiency, are at high risk of arterial or venous thrombotic diseases, or have ever had a stroke, heart attack or blood clots in the legs, lungs or eyes.
The drug is also contraindicated in women who have undiagnosed abnormal uterine bleeding. Do not take Yaz if you have or had breast cancer or other estrogen- or progestin-sensitive cancer, or if you are pregnant. The use of contraceptive steroids may also influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance and binding proteins.
Ingesting certain medications, whether prescription or ocer-the-counter (OTC), as well as other vitamins, supplements or other substances in combination with Yaz, can alter the effects of the pills or cause unknown side effects.
If you are currently taking Yaz, or prior to taking Yaz, always check with a doctor before taking (or if you are already taking) the following medications or supplements:
- ACE inhibitors – drugs used to treat high blood pressure and other conditions, such as the prevention of heart attacks, heart failure and the progression of kidney disease in certain individuals
- Antibiotics – used in the treatment and prevention of bacterial infections, these medications can interfere with the effectiveness of birth control pills, such as Yaz
- Heparin – an injectable drug used to prevent and treat blood clots in the veins, arteries or lungs
- Morphine – a narcotic pain reliever used to treat moderate to severe pain
- Diuretics – a substance that promotes the increased production of urine
- Salicylic acid – commonly used for dermatological (affecting the skin) conditions, such as acne
- St. John’s wort – a flowering plant (medicinal herb) with antidepressant and anti-inflammatory properties
- Vitamin C – also known as ascorbic acid, it is a vitamin found in food and used as a dietary supplement
Yaz Side Effects
The most common side effects of Yaz are spotting or bleeding between menstrual periods, nausea, breast tenderness and headache. These side effects are usually mild and tend to disappear with time.
Less common side effects include:
- Less sexual desire
- Bloating or fluid retention
- Blotchy darkening of the skin (especially on the face)
- High blood sugar
- High fat levels in the blood
- Problems tolerating contacts
- Weight changes
In clinical trials for Yaz, in women being treated for PMDD symptoms, the following frequencies of side effects were reported:
of women reported irregular bleeding
reported breast tenderness
In contraception and acne trials, the following frequencies of side effects were reported:
of patients reported headache and/or migraine
reported nausea and/or vomiting
reported breast pain and tenderness
reported mood changes
FDA Yaz Warnings
Yaz’ drug label also warns of serious complications, including heart attack, stroke, deep vein thrombosis (blood clots in the legs), pulmonary embolism (blockages in the lungs), gallbladder disease, high blood pressure, elevated potassium levels, and liver tumors or disease.
In December 2008, an FDA panel voted in favor of strengthening warnings on Yaz birth control pill labels. The FDA’s most serious label, the black-box warning, appears on all Yaz packaging. It cautions women over 35 years old who smoke not to use Yaz. Smoking increases the risk of serious cardiovascular events, which can be life-threatening. This risk increases with age and number of cigarettes smoked.
In 2009, the FDA sent a warning letter to Bayer, the maker of Yaz, regarding the quality of ingredients found during a routine inspection of the manufacturing plant in Germany. The problems at the plant included dirty equipment and failure to adequately test the final products. At least eight batches of the low-quality birth control pills were sent to the U.S.
Then, following a safety review, the FDA in 2012 updated Yaz labels to include information about studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills, including Yaz. The revised drug labels state that some studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products when compared to products containing other progestins; other studies found no additional risk of blood clots with these products.
Over the years, the drug has been linked to 50 deaths in women as young as 17 and hundreds of injuries.
Yaz hit the market in 2006. By 2008, it was the best-selling birth control pill in the U.S., and its sales totaled $781 million in 2009.
Women worldwide were enticed by the splashy advertising that portrayed Yaz as a new generation of birth control that could not only prevent pregnancy but also help women lose weight, cure acne at any level of severity and help with premenstrual moodiness. Some of the commercials used balloons; others depicted euphoric women singing, “We’re Not Gonna Take It,” as they kicked and punched words such as “irritability,” “moodiness” and “bloating.”
Between 2007 and 2010, Bayer spent more than $270 million on advertising for the drug — the likes of which had never been seen in the U.S.
The drug was touted as not just a contraceptive but also a cure-all for premenstrual dysphoric disorder, bloating and acne at any level of severity. In addition to preventing pregnancy, Yaz was also marketed by Bayer as a treatment for PMS, an off-label, or unapproved use.
By 2009, the FDA reined in the advertising and forced Bayer to spend $20 million on new ads to correct the off-label Yaz marketing and exaggerated claims.
The agency said the advertising was misleading, over-promised benefits, downplayed risks and encouraged unapproved uses of Yaz.
According to the FDA, prescription drug promotion cannot be false or misleading. It must have a fair balance, be consistent with approved product labeling or the packaging insert, and must only include claims substantiated by adequate and well-controlled clinical studies.
FDA Warns of Misleading Yaz Advertising
According to the FDA, the Yaz commercials wrongly suggested that the drug was approved to treat PMS and acne at any level of severity when in actuality, the drug is only approved to treat PMDD and moderate acne. The FDA also complained that Bayer overstated the effectiveness of the contraceptive to treat both conditions.
The agency told Bayer that it had minimized the drug’s risks. The commercials’ audio and visual effects distracted viewers from the most important part of the commercial. Quick-changing scenes combined with background music took attention away from the part that disclosed the drug’s risks, according to the FDA.
Bayer denied wrongdoing but agreed to pull the commercials. The company also ran a series of corrective TV ads at the request of the FDA and changed its commercials. Still, problems with how Bayer disclosed information about Yaz continued. Three years after the FDA’s warning about the commercials, an FDA document acknowledged that studies raised questions about the safety of Yaz and its related contraceptives. Scientists have recommended more testing and better labeling to warn about possible risks. Some critics have even recommended recalling the drug altogether.
About 32,856 boxes of Yaz (at three packs per box) that had been distributed nationwide were recalled in 2009. The issue cited was with the specifications for the dosage of drospirenone in the pill. Bayer had taken an analytical value that was “out of specification” and averaged it together with another analytical value to get the number needed to be “within specification.”
The FDA published the recall on November 25, 2009, in the “Enforcement Report” section of its website as opposed to the “Recalls, Market Withdrawls, & Safety Alerts” section. The agency had inspected Bayer on this same issue in March 2009 and warned the company about its averaging practice in August 2009.
Aside from this limited recall, Yaz has remained on the market.
Studies Prompt Some to Call for Complete Yaz Recall
Within months of Yaz hitting the market, stories about Yaz-induced medical problems started cropping up. Even though industry-funded studies found no links between Yaz and the assortment of medical problems early on, independent researchers started delving in.
Soon, the FDA’s own study found a 74 percent increased risk of blood clots among those taking drospirenone containing pills, prompting some to call for a Yaz recall. Bayer shot back, contending that there were no risks with this drug above the already documented risks with birth control pills overall and therefore no reason to recall the drug.
Instead of making a final decision about whether or not to recall Yaz, the FDA asked an advisory committee to look into the pill. The FDA often uses independent advisory committees, made up of medical specialists in particular fields, to come up with recommendations. The committee did not recommend that Yaz be recalled.
Allegations of Bayer-FDA Connection
Members of the nonprofit Project on Government Oversight (POGO) have called the advisory committee’s actions into question. The group pointed out that four committee members, including the committee chair, had financial ties to Bayer. None of the committee members had disclosed any conflicts of interest when making decisions about Yaz.
“Because of the industry ties of these members, the joint committee’s conclusion—which amounted to an endorsement of the safety of these oral contraceptives—should be disregarded,” POGO executive director Danielle Brian wrote to FDA Commissioner Margaret Hamburg.
Consumer watchdogs continue to express concerns about the drug’s safety when compared to other birth control pills and are calling for a stringent review of federal regulators, the drug and the drug maker. Thousands of women who say they were harmed by Yaz have turned to the legal system for help with Yaz-related damages. More than 11,000 patients have filed Yaz lawsuits against Bayer. Bayer has paid at least $750 million to settle thousands of those lawsuits.
Hormonal Versus Non-Hormonal Contraceptives: What’s the Harm?
Since the occurrences of adverse events in patients taking various medications often go unreported to the FDA, many experts say it is impossible to know precisely how many women have died as a direct result of taking Yaz.
While hormonal contraceptives have been shown to provide some women with measurable benefits, one expert in the field says we don’t know enough about the benefits afforded to women if they choose not to take them, and thereby we are lacking the ability to conclude a true benefit versus risk comparison.
Cynthia Pearson of the National Women’s Health Network weighed in as a part of a blog post for menstruation research, voicing her concerns that not enough is being done by the federal agency to protect the female population from the dangers of contraception containing hormones.
“When I heard that the FDA was asking for a comparison between pregnancy risks and risks of Yaz and Yasmin, and that the women’s health groups were calling for, in their letter to the FDA, a comparison between these oral contraceptives and other brands not containing drospirenone, I immediately wanted to know why the comparison was not between using these pills and not using them – as in using other forms of non-hormonal contraception with similar effectiveness.”
- Cynthia Pearson, National Women’s Health Network
Pearson believes this would provide women and their doctors prescribing these medicines with the “biggest gap,” putting the statistics in “starker relief.” Pearson says there is “too much dependent on the FDA not acknowledging the efficacy of non-hormonal contraceptives.” She also pointed out that the FDA fails to admit that “research funded by the pharmaceutical company producing the drug is not reliable.”
In Pearson’s mind, the FDA’s behavior “should raise some serious suspicions of their motivating force.”
Pearson also pointed out that the federal agency advising women to consult with their doctors is not wise, as many doctors lack specific knowledge of the drugs they are prescribing, due to time constraints, inclination, and the potential for direct or indirect benefits being derived from the backing the drugmakers themselves.
In conclusion, Pearson wondered “if it’s taken this long to get a tentative admission of the blood clot risk [associated with Yaz], what do we not know about the other side effects of these pills?”
Kristin Compton is a medical writer with a background in legal studies. She has experience working in law firms as a paralegal and legal writer. She also has worked in journalism and marketing. She’s published numerous articles in a northwest Florida-based newspaper and lifestyle/entertainment magazine, as well as worked as a ghost writer on blog posts published online by a Central Florida law firm in the health law niche. As a patient herself, and an advocate, Kristin is passionate about “being a voice” for others.
- Bayer Healthcare. (n.d.). Highlights of Prescribing Information. Retrieved from: http://labeling.bayerhealthcare.com/html/products/pi/fhc/YAZ_PI.pdf
- Becerra, X., State of California Department of Justice. (2009 February 9). Brown Requires Bayer to Launch $20 Million Ad Campaign to Correct Misleading Information about Oral Contraceptive. Retrieved from: https://oag.ca.gov/news/press-releases/brown-requires-bayer-launch-20-million-ad-campaign-correct-misleading
- Brian, D. (2012, January 11). POGO letter: FDA Advisors on Yaz and Yasmin Have Industry Ties. Project on Government Oversight.
- Burger, L. (2012 October 30). Bayer to buy U. S. vitamin maker Schiff for $1.2 bln. Reuters. Retrieved from: http://www.reuters.com/article/2012/10/30/bayer-schiff-idUSL5E8LU0LY20121030
- Creative Commons. (n.d.). Yaz. Retrieved from: https://pillbox.nlm.nih.gov/assets/large/50419-0405-01_SPLIMAGE30_C11960EB.jpg
- Cuomo, C.; Pearle, L. and Ruppel, G. (2011). New Studies Find Yaz More Risky Than Other Leading Birth Control Pills: ABC News Investigates. Retrieved from: http://abcnews.go.com/TheLaw/studies-find-yaz-risky-leading-birth-control-pills/story?id=14741760
- Deardorff, J. (2013, September 15). Lawsuits pile up over popular birth control pill. Retrieved from: http://articles.chicagotribune.com/2013-09-15/health/ct-met-birth-control-risks-20130915_1_drospirenone-clots-pills/2
- FDA. (2007). Drug Approval Package. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000TOC.cfm
- FDA. (2011). FDA Drug Safety Communication: Safety Review of possible increased risk of blood clots with birth control pills containing drospirenone. Retrieved from: https://www.fda.gov/Drugs/DrugSafety/ucm257164.htm
- FDA. (2012). FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Retrieved from: https://www.fda.gov/Drugs/DrugSafety/ucm299305.htm
- FDA. (2012). Yaz (drospirenone/ethinyl estradiol): Full Prescribing Information. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021676s012lbl.pdf
- Gardener, A. (2011, September 27). FDA turns to advisory panel for Yaz safety analysis. USA Today.
- Johns Hopkins Medicine. (N.D.). Premenstrual Dysphoric Disorder (PMDD). Retrieved from: http://www.hopkinsmedicine.org/healthlibrary/conditions/gynecological_health/premenstrual_dysphoric_disorder_pmdd_85,P00580/
- Kissling, E. and Grigg-Spall, H. (2012). “Lives will be saved” – the FDA decision not to ban Bayer’s birth control pill. Retrieved from: http://www.menstruationresearch.org/2012/04/18/%E2%80%9Clives-will-be-saved%E2%80%9D-%E2%80%93-the-fda-decision-not-to-ban-bayer%E2%80%99s-birth-control-pill/
- MedlinePlus, NIH. (2015). Acne. Retrieved from: https://medlineplus.gov/ency/article/000873.htm
- MedlinePlus, NIH. (2016). Acne. Retrieved from: https://medlineplus.gov/acne.html
- MedlinePlus, NIH. (2016). Premenstrual dysphoric disorder. Retrieved from: https://medlineplus.gov/ency/article/007193.htm
- MedlinePlus, NIH. (2016). Premenstrual Syndrome. Retrieved from: https://medlineplus.gov/premenstrualsyndrome.html
- MedlinePlus, NIH. (2017). Menstruation. Retrieved from: https://medlineplus.gov/menstruation.html
- Monson, K, et al. (2010, June 6). Yaz. eMedTV. Retrieved from: http://women.emedtv.com/yaz/yaz.html
- Planned Parenthood. (2017). Birth Control Pill. Retrieved from: https://www.plannedparenthood.org/learn/birth-control/birth-control-pill
- Stacy, PhD, LMHC, D. (2016). Are Yaz Birth Control Pills For You? Retrieved from: https://www.verywell.com/what-is-yaz-birth-control-906835
- Stacy, PhD, LMHC, D. (2016). Understanding The Role of Progestin in Birth Control. Retrieved from: https://www.verywell.com/understanding-the-role-of-progestin-in-birth-control-906932
- U.S. Food & Drug Administration. (2009, November 25). Enforcement Report for November 25, 2009. Retrieved from: https://www.fda.gov/Safety/Recalls/EnforcementReports/ucm192035.htm
- Yaz-us.com. (n.d.). Indications & Usage. Retrieved from: http://www.yaz-us.com/